LOGIN  |  REGISTER
Cue Biopharma
Viking Therapeutics

Chemed Declares Quarterly Dividend of 50 Cents

August 02, 2024 | Last Trade: US$552.87 5.53 1.01

CINCINNATI / Aug 02, 2024 / Business Wire / Chemed Corporation (NYSE:CHE) announced today that the Board of Directors has declared a quarterly cash dividend of 50-cents per share on the Company’s capital stock, payable on August 30, 2024, to shareholders of record as of August 12, 2024. This is a 10-cent, or 25.0%, increase over the 40-cent dividend paid in June 2024. The previous increase was in August 2023, when the Board raised the quarterly dividend from 38-cents to 40-cents per share. This represents the 213th consecutive quarterly dividend paid by Chemed in its 53 years as a public company.

Listed on the New York Stock Exchange and headquartered in Cincinnati, Ohio, Chemed Corporation (www.chemed.com) operates two wholly owned subsidiaries: VITAS Healthcare and Roto-Rooter. VITAS is the nation's largest provider of end-of-life hospice care and Roto-Rooter is the nation’s leading provider of plumbing and drain cleaning services.

Statements in this press release or in other Chemed communications may relate to future events or Chemed's future performance. Such statements are forward-looking statements and are based on present information Chemed has related to its existing business circumstances. Investors are cautioned that such forward-looking statements are subject to inherent risk that actual results may differ materially from such forward-looking statements. Further, investors are cautioned that Chemed does not assume any obligation to update forward-looking statements based on unanticipated events or changed expectations.

Recursion

Stock Quote

Featured Stock

Amneal Pharmaceuticals

Amneal Pharmaceuticals is a fully-integrated essential medicines company. We make healthy possible through the development, manufacturing, and distribution of generic and specialty pharmaceuticals. The Company has a diverse portfolio of over 250 products in its Generics segment and is expanding across...

CLICK TO LEARN MORE

Featured Stock

Astria Therapeutics

Astria Therapeutics is a biopharmaceutical company, and our mission is to bring life-changing therapies to patients and families affected by rare and niche allergic and immunological diseases. Our lead program, STAR-0215, is a monoclonal antibody inhibitor of plasma kallikrein in clinical development...

CLICK TO LEARN MORE

End of content

No more pages to load

Next page

COPYRIGHT ©2023 HEALTH STOCKS HUB